{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:33:25Z","timestamp":1761744805482,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.dsx.2020.11.019","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T12:20:26Z","timestamp":1606134026000},"page":"13-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term efficacy and safety of anti-hyperglycaemic agents in new-onset diabetes after transplant: Results from outpatient-based 1-year follow-up and a brief review of treatment options"],"prefix":"10.1016","volume":"15","author":[{"given":"Debmalya","family":"Sanyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansij","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayan","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dsx.2020.11.019_bib1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41574-018-0137-7","article-title":"Post-transplant diabetes mellitus in patients with solid organ transplants","volume":"15","author":"Jenssen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"10.1016\/j.dsx.2020.11.019_bib2","article-title":"New-onset diabetes after transplantation: international consensus guidelines","volume":"75","author":"Davidson","year":"2003","journal-title":"Proceedings of an international expert panel meeting. Transplantation"},{"key":"10.1016\/j.dsx.2020.11.019_bib3","doi-asserted-by":"crossref","first-page":"107948","DOI":"10.1016\/j.diabres.2019.107948","article-title":"An observational prospective study to evaluate the outcomes of new onset diabetes after renal transplantation (NODAT) in a tertiary care centre in eastern India","volume":"159","author":"Kumar","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.dsx.2020.11.019_bib4","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions","volume":"14","author":"Sharif","year":"2014","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.dsx.2020.11.019_bib5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/ndt\/gfz244","article-title":"Cardiovascular events associate with diabetes status rather than with early basal insulin treatment for the prevention of post-transplantation diabetes mellitus","volume":"35","author":"Topitz","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.dsx.2020.11.019_bib6","doi-asserted-by":"crossref","first-page":"145-53","DOI":"10.1016\/j.trre.2015.01.001","article-title":"Antidiabetic therapy in post kidney transplantation diabetes mellitus","volume":"29","author":"Werzowa","year":"2015","journal-title":"Transplant Rev"},{"issue":"10","key":"10.1016\/j.dsx.2020.11.019_bib7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/00007890-200105270-00011","article-title":"beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus","volume":"71","author":"Nam","year":"2001","journal-title":"Transplantation"},{"issue":"20","key":"10.1016\/j.dsx.2020.11.019_bib8","first-page":"30932","article-title":"Glucose metabolism after kidney transplantation: insulin release and sensitivity with tacrolimus- versus belatacept-based immunosuppression","volume":"S0272\u20136386","author":"M\u00fcller","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.dsx.2020.11.019_bib9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17425255.2018.1530214","article-title":"Glucocorticoids use in kidney transplant setting","volume":"14","author":"De Lucena","year":"2018","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"1","key":"10.1016\/j.dsx.2020.11.019_bib10","first-page":"1","article-title":"Two decades of tacrolimus in renal transplant: basic science and clinical evidences","volume":"15","author":"Shrestha","year":"2017","journal-title":"Exp Clin Transplant"},{"issue":"2","key":"10.1016\/j.dsx.2020.11.019_bib11","doi-asserted-by":"crossref","first-page":"E365","DOI":"10.1152\/ajpendo.00390.2004","article-title":"Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity","volume":"288","author":"Radu","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.dsx.2020.11.019_bib12","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.transproceed.2004.12.085","article-title":"Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus","volume":"37","author":"Oberholzer","year":"2005","journal-title":"Transplant Proc"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.dsx.2020.11.019_bib13","first-page":"s1","article-title":"Standards of medical care in diabetes 2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2020.11.019_bib14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2215\/CJN.05471008","article-title":"Hyperglycemia during the immediate period after kidney transplantation","volume":"4","author":"Chakkera","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.dsx.2020.11.019_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF03261927","article-title":"Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors","volume":"51","author":"Golightly","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dsx.2020.11.019_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"J\u00a0Am Med Assoc"},{"issue":"6","key":"10.1016\/j.dsx.2020.11.019_bib17","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/TP.0000000000001252","article-title":"Long-term outcomes of living kidney donation","volume":"100","author":"Slinin","year":"2016","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.dsx.2020.11.019_bib18","first-page":"2","article-title":"Kidney transplant in diabetic patients: modalities, indications and results","volume":"1","author":"Rangel","year":"2009","journal-title":"DiabetolMetabSyndr"},{"issue":"5","key":"10.1016\/j.dsx.2020.11.019_bib19","first-page":"610","article-title":"An observational prospective study to evaluate the preoperative risk factors of new-onset diabetes mellitus after renal transplant in a tertiary care centre in eastern India","volume":"22","author":"Kumar","year":"2018","journal-title":"Indian J EndocrMetab"},{"issue":"7","key":"10.1016\/j.dsx.2020.11.019_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4239\/wjd.v9.i7.132","article-title":"New-onset diabetes after kidney transplantation: incidence and associated factors","volume":"9","author":"Gomes","year":"2018","journal-title":"World J Diabetes"},{"issue":"1","key":"10.1016\/j.dsx.2020.11.019_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1210\/er.2015-1084","article-title":"Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes","volume":"37","author":"Shivaswamy","year":"2016","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.dsx.2020.11.019_bib22","first-page":"273","article-title":"Prevalence and predictors of \u201cnew-onset diabetes after transplantation\u201d (NODAT) in renal transplant recipients: an observational study","volume":"23","author":"Choudhury","year":"2019","journal-title":"Indian J EndocrMetab"},{"issue":"4","key":"10.1016\/j.dsx.2020.11.019_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.dsx.2020.11.019_bib24","first-page":"CD009966","article-title":"Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients","volume":"2","author":"Lo","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.dsx.2020.11.019_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/TP.0b013e3181605ebf","article-title":"Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia","volume":"85","author":"Sharif","year":"2008","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.dsx.2020.11.019_bib26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1681\/ASN.2011080835","article-title":"Early basal insulin therapy decreases new-onset diabetes after renal transplantation","volume":"23","author":"Hecking","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.dsx.2020.11.019_bib27","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/j.1600-6143.2011.03550.x","article-title":"Should metformin be our antiglycemic agent of choice post-transplantation?","volume":"11","author":"Sharif","year":"2011","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.dsx.2020.11.019_bib28","doi-asserted-by":"crossref","first-page":"903-10","DOI":"10.1001\/jamainternmed.2018.0292","article-title":"Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study","volume":"178","author":"Lazarus","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.dsx.2020.11.019_bib29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1159\/000370034","article-title":"Metformin use in kidney transplant recipients in the United States: an observational study","volume":"40","author":"Stephen","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.dsx.2020.11.019_bib30","first-page":"100225","article-title":"Metformin adherence and discontinuation among patients with type 2 diabetes: a retrospective cohort study","volume":"20","author":"Tang","year":"2020","journal-title":"J\u00a0Clin Transl Endocrinol"},{"issue":"12","key":"10.1016\/j.dsx.2020.11.019_bib31","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/j.1600-6143.2004.00613.x","article-title":"Pioglitazone in the management of diabetes mellitus after transplantation","volume":"4","author":"Luther","year":"2004","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.dsx.2020.11.019_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1432-2277.2004.00076.x","article-title":"Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation","volume":"18","author":"Pietruck","year":"2005","journal-title":"Transpl Int"},{"issue":"8","key":"10.1016\/j.dsx.2020.11.019_bib33","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4158\/EP.14.8.979","article-title":"Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients","volume":"14","author":"Kurian","year":"2008","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.dsx.2020.11.019_bib34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00592-018-1137-8","article-title":"Post-transplantation diabetes in kidney transplant recipients: an update on management and prevention","volume":"55","author":"Conte","year":"2018","journal-title":"Acta Diabetol"},{"issue":"4","key":"10.1016\/j.dsx.2020.11.019_bib35","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ndt\/gft536","article-title":"Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation","volume":"29","author":"Halden","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.dsx.2020.11.019_bib36","first-page":"617638","article-title":"Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation","volume":"2014","author":"Boerner","year":"2014","journal-title":"Internet J Endocrinol"},{"issue":"1","key":"10.1016\/j.dsx.2020.11.019_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/ajt.12518","article-title":"Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation- A randomized, double-blind, placebo-controlled trial","volume":"14","author":"Haidinger","year":"2014","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.dsx.2020.11.019_bib38","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/TP.0b013e318276a20e","article-title":"Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo controlled clinical trial","volume":"95","author":"Werzowa","year":"2013","journal-title":"Transplantation"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.dsx.2020.11.019_bib39","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.4103\/2230-8210.119572","article-title":"A\u00a0retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting","volume":"17","author":"Sanyal","year":"2013","journal-title":"Indian J EndocrinolMetab"},{"issue":"2","key":"10.1016\/j.dsx.2020.11.019_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.trre.2016.09.001","article-title":"Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus","volume":"31","author":"Vanhove","year":"2017","journal-title":"Transplant Rev"},{"issue":"1","key":"10.1016\/j.dsx.2020.11.019_bib41","doi-asserted-by":"crossref","first-page":"43-51","DOI":"10.1016\/S2213-8587(14)70213-X","article-title":"Mortality risk among sulfonylureas: a systematic review and network meta-analysis","volume":"3","author":"Simpson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.dsx.2020.11.019_bib42","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1600-6143.2006.01250.x","article-title":"Repaglinide in the management of new-onset diabetes mellitus after renal transplantation","volume":"6","author":"T\u00fcrk","year":"2006","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.dsx.2020.11.019_bib43","doi-asserted-by":"crossref","first-page":"814","DOI":"10.4158\/EP14569.RA","article-title":"The rationale for use of incretins in the management of new onset diabetes after transplantation (NODAT)","volume":"21","author":"Sadhu","year":"2015","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.dsx.2020.11.019_bib44","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.2337\/dc13-1066","article-title":"Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series","volume":"36","author":"Pinelli","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2020.11.019_bib45","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/dom.13619","article-title":"Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients","volume":"21","author":"Singh","year":"2019","journal-title":"Diabetes Obes Metabol"},{"issue":"9","key":"10.1016\/j.dsx.2020.11.019_bib46","doi-asserted-by":"crossref","first-page":"525-6","DOI":"10.1038\/s41581-019-0173-0","article-title":"Considerations for SGLT2 inhibitor use in post-transplantation diabetes","volume":"15","author":"Hecking","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.dsx.2020.11.019_bib47","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2337\/dc17-0237","article-title":"Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series","volume":"40","author":"Rajasekeran","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2020.11.019_bib48","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijn.IJN_2_18","article-title":"Efficacy and safety of canagliflozin in kidney transplant patients","volume":"29","author":"Shah","year":"2019","journal-title":"Indian J Nephrol"},{"issue":"3","key":"10.1016\/j.dsx.2020.11.019_bib49","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional study on glucose metabolism, fluid volume, and patient safety","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.dsx.2020.11.019_bib50","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120304847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120304847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:14:42Z","timestamp":1761729282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402120304847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1871402120304847"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2020.11.019","relation":{},"ISSN":["1871-4021"],"issn-type":[{"type":"print","value":"1871-4021"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of anti-hyperglycaemic agents in new-onset diabetes after transplant: Results from outpatient-based 1-year follow-up and a brief review of treatment options","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2020.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}